What Is Neuro-EDS?

Neuro-EDS is a newly proposed clinical phenotype describing people with hypermobile Ehlers-Danlos syndrome, hypermobility spectrum disorder, or a related heritable connective tissue disorder whose illness is dominated by neurological, craniospinal, autonomic, and inflammatory manifestations.

It is not currently an officially recognized EDS subtype, a separate diagnosis, or an established indication for a particular treatment.

The term received new attention in August 2026 after six clinicians and researchers published a position paper titled “Defining Neuro-EDS: A Neuro-Predominant Phenotype in hEDS/HSD and Related Heritable Connective Tissue Disorders”. The paper proposes a framework for studying patients whose complex neurological problems may be difficult to understand when every condition is evaluated in isolation.

The proposal is potentially important, but it remains preliminary. The paper is a preprint that had not undergone peer review when published.

Neuro-EDS at a glance

• Neuro-EDS is a proposed phenotype, not a new type of EDS.
• It is primarily associated with hEDS, HSD, and related heritable connective tissue disorders.
• The framework contains two overlapping domains.
• One domain covers cranial, spinal, cerebrospinal-fluid, and venous conditions.
• The other covers neurological, autonomic, inflammatory, and systemic manifestations.
• There are no accepted Neuro-EDS diagnostic criteria, genetic tests, or treatment guidelines.
• Researchers still need to determine whether the conditions share an underlying biological mechanism.

Where did the Neuro-EDS proposal come from?

Neuro-EDS did not emerge from a blank slate. A 2017 review described neurological and spinal complications associated with EDS. In 2024, a study of self-reported data from 2,149 people with hEDS identified three phenotypic clusters. One had a higher prevalence of neurological and spinal conditions. Neither paper defined Neuro-EDS or established it as a diagnosis, but both document the earlier clinical and research context.

That context was visible at the Ehlers-Danlos Society’s 2026 Global Learning Conference. On July 23, the Society held an educational screening of Complicated, a documentary filmed over seven years about young people with EDS and their families seeking diagnosis and care. One of the cases featured in the film may resemble the phenotype later described as Neuro-EDS, giving the emerging clinical idea a vivid connection to patients’ lived experiences.

The next day, Neuro-EDS appeared by name in the conference program. During “But It’s Not Connected...Or Is It? The Overlooked Links in EDS & HSD,” Dr. Paolo Bolognese presented “Neuro EDS: Defining a Neurological Phenotype in Hypermobile Connective Tissue Disorders.” The initial presentation generated considerable buzz. A little over two weeks later, on August 10, the discussion moved from a conference session to a posted preprint. The preprint paper is called, “Defining Neuro-EDS: A Neuro-Predominant Phenotype in hEDS/HSD and Related Heritable Connective Tissue Disorders”. This position paper formally proposes Neuro-EDS as a phenotype for further study. It is a preprint and was not peer-reviewed when originally posted.

Multiple thought leaders soon followed with articles and posts about Neuro-EDS. Biomedical researcher Cortney Gensemer published a review of the proposal, and Chronic Pain Partners published a patient-oriented explanation. These articles, together with posts from other EDS advocates and influencers, added to the buzz. The question now circulating through the community is a simple one: what is Neuro-EDS?

What does the proposed Neuro-EDS phenotype include?

A phenotype is a recognizable pattern of observable features. It is not necessarily a separate disease or genetic subtype. Calling Neuro-EDS a phenotype means the authors believe a recurring pattern may be worth studying. It does not mean they have identified a new EDS gene or a single cause connecting every condition.

The authors frame Neuro-EDS through a network medicine model. Instead of treating every diagnosis as isolated, this approach examines how clinical features and biological processes cluster and interact.

The paper organizes the proposal into two overlapping domains.

The cranial and spinal domain includes conditions involving the skull, neck, spine, cerebrospinal fluid, and venous drainage. Examples include Chiari I malformation, craniocervical or atlantoaxial instability, tethered cord syndrome, spontaneous cerebrospinal-fluid leaks, intracranial pressure disorders, and cerebral venous outflow problems. Readers can find background in The EDS Clinic’s guides to Chiari malformation and EDS, craniocervical instability, and tethered cord syndrome.

The neuro-autonomic-inflammatory domain includes POTS and other forms of dysautonomia, small-fiber neuropathy, neuropathic pain, gastrointestinal dysmotility, mast-cell activation disorders, migraine, sleep disturbance, cognitive problems, fatigue, and exercise intolerance. The paper proposes that these manifestations may interact with craniospinal disease. That remains a hypothesis, not proof that a structural abnormality causes every symptom.

Symptoms associated with the framework may include headaches, neck or back pain, dizziness, fainting, numbness, burning pain, weakness, balance problems, brain fog, fatigue, sleep problems, gastrointestinal symptoms, and bladder dysfunction.

The Center for Neuro-EDS and Craniospinal Disorders, formerly called the Chiari EDS Center, describes its work broadly in terms of Neuro-EDS and craniospinal disorders.

Many of these symptoms, alone or in combination, are nonspecific. Still, the proposed pattern is worth examining. The framework comes from clinicians and researchers with experience in complex EDS presentations, and many patients in the community recognize aspects of their own illness in it. Even if the boundaries of Neuro-EDS are not yet definitive, studying the pattern may lead to a deeper understanding of the biology and pathology of EDS and its neurological presentations.

What evidence supports Neuro-EDS?

The proposal draws heavily on a 2024 cluster analysis of 2,149 people with clinically diagnosed hEDS. One of three clusters had more neurological and spinal conditions and averaged more than 14 co-occurring conditions. The Neuro-EDS paper interprets this cluster as representing roughly 10% to 15% of the study cohort.

That is not a population estimate of Neuro-EDS prevalence. The study was cross-sectional, relied substantially on self-reported registry data, and included a predominantly non-Hispanic White female population. It identified a recurring pattern, not a distinct biological cause.

The position paper also cites research on Chiari malformation, craniocervical instability, tethered cord, cerebrospinal-fluid leaks, small-fiber neuropathy, dysautonomia, POTS, and mast-cell disorders. Together, this literature supports further study of the proposed cluster. It does not establish Neuro-EDS as one unified condition.

Is Neuro-EDS an official diagnosis?

No. Neuro-EDS is not currently an official EDS diagnosis.

The 2017 International Classification recognizes 13 EDS types, and Neuro-EDS is not among them. No validated Neuro-EDS criteria or dedicated ICD-10 code exist.

The EDS field has other informal names for recurring clusters. The EDS Triad or Trifecta refers to EDS or HSD occurring with POTS and MCAS. The Pentad Super Syndrome adds autoimmune and gastrointestinal dysfunction. These terms may help describe patterns, but they are not stand-alone diagnoses. Neuro-EDS is also a proposed organizing framework.

The EDS and HSD classification is scheduled for an update in December 2026. It is not yet known whether that publication will address Neuro-EDS. Learn more about the December 2026 EDS criteria update.

Is there a Neuro-EDS test or treatment?

There is no single Neuro-EDS test, confirmed gene, unique imaging finding, consensus checklist, or validated treatment protocol. Individual conditions within the framework have their own diagnostic approaches. Evaluation should be based on a person’s symptoms, examination, and established clinical criteria rather than an attempt to collect every condition associated with the label.

The preprint discusses the possibility that some craniospinal conditions may be dynamic or difficult to detect with static imaging. This does not mean everyone with hEDS and neurological symptoms needs positional imaging, invasive testing, or a surgical consultation.

Care should focus on confirmed diagnoses, the most disabling symptoms, functional limitations, and individual risks. The Neuro-EDS label alone is not an indication for cervical traction, prolonged bracing, invasive testing, or surgery.

What are the limitations, and why might the concept matter?

The defining paper is a position paper, not a prospective diagnostic-validation study, and it had not undergone peer review when posted. Some supporting evidence also comes from registries and specialist centers that see unusually complex cases.

One retrospective neurosurgical cohort study illustrates the problem. Of 460 patients with hEDS seen at the center, 404 chose surgery, and 73% of those underwent craniocervical fusion. These figures describe a highly selected surgical-referral population. They cannot be generalized to everyone with hEDS.

Researchers still need to determine which features define the phenotype, whether its two domains share a biological mechanism, how it differs from other neurological disorders, and whether recognizing it improves outcomes. Independent replication will be essential.

The potential value is organizational. People with complex hEDS or HSD may receive care from several specialists for headaches, POTS, neuropathic pain, fatigue, or spinal symptoms. The authors argue that a shared framework could support more consistent multidisciplinary care, standardized phenotyping, multicenter registries, natural-history studies, and research into biological endotypes. These are proposed benefits, not demonstrated outcomes.

The evidence base for some component conditions also remains unsettled. For example, a 2022 systematic review of craniocervical instability in EDS reported limited evidence and inconsistent diagnostic and surgical criteria.

Another experimental question is whether studying the cluster as an interacting system could reveal more about its mechanobiology: how connective-tissue properties, mechanical forces, and cellular responses may influence one another. Learn more about mechanobiology in EDS, ME/CFS, MCAS, and POTS.

For now, Neuro-EDS is best understood as a proposed pattern rather than a finished medical category.

Frequently asked questions

Is Neuro-EDS real?

The symptoms and diagnosed conditions discussed in the framework are real. What remains unproven is whether they form one biologically unified phenotype.

Is Neuro-EDS the same as neurodivergence?

No. Neuro-EDS refers to proposed neurological and systemic disease manifestations. Neurodivergence generally refers to variations such as autism or ADHD. The terms are not interchangeable. Some research has linked Hypermobility with Neurodivergence including ADHD and Autism.

How common is Neuro-EDS?

Its prevalence is unknown. The widely repeated 10–15% figure is derived from interpreting a neurological cluster in one hEDS research cohort, not a population prevalence study.

Who diagnoses Neuro-EDS?

No specialty can make a standardized Neuro-EDS diagnosis because accepted criteria do not exist. Clinicians can evaluate hEDS, HSD, neurological symptoms, and the individual conditions included in the proposal.

Sources

1. Bloom AR, Ruhoy IS, Dass RA, Lerner A, Bolognese PA, Klinge PM. Defining Neuro-EDS: A Neuro-Predominant Phenotype in hEDS/HSD and Related Heritable Connective Tissue Disorders. Preprints. 2026. Preprint/position paper; not peer-reviewed when posted.
2. Petrucci T, et al. Phenotypic Clusters and Multimorbidity in Hypermobile Ehlers-Danlos Syndrome. Mayo Clinic Proceedings: Innovations, Quality & Outcomes. 2024.
3. Ruhoy IS, et al. Comorbidities and Neurosurgical Interventions in a Cohort With Connective Tissue Disorders. Frontiers in Neurology. 2025;15:1484504.
4. Teti J. What Is “Neuro-EDS” and Why Are People Talking About It?. Chronic Pain Partners/EDS Awareness. August 15, 2026.

‍

Medical note: This article is for general information and does not provide medical advice or diagnosis. New weakness, difficulty speaking, loss of consciousness, a severe sudden headache, or new bowel or bladder dysfunction requires prompt medical assessment.